Denifanstat Drug Asset Due Diligence Report 2026

This Denifanstat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Denifanstat can convert its Small molecule drug profile and FASN biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Denifanstat (query alias: denifanstat)
Modality / target	Small molecule drug; FASN; FAS inhibitors
Highest global status	NDA/BLA
Originator	Sagimet Biosciences, Inc.
Active developers	Ascletis BioScience Co., Ltd., Sagimet Biosciences, Inc., Ascletis Pharmaceuticals Co., Ltd.

The MCP disease footprint includes Acne Vulgaris, Recurrent Glioblastoma, Metabolic Dysfunction Associated Steatohepatitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600126528	Phase 3	Completed	240	Number and percentage of subjects with treatment-phase adverse events (TEAE)
ChiCTR2500111094	Phase 3	Completed	240	Investigator-assessed (IGA) percentage of treatment success
NCT06692283	Phase 3	Withdrawn	Not disclosed	Primary Safety Outcome Measure: TEAEs

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A phase 2 multi-center pharmacodynamic study of the fatty acid synthase (FASN) inhibitor TVB-2640 in advanced KRAS-mutant non–small cell lung cancer.

Phase 2; n=18; evaluation: Negative. Reported fields: AE = 84.0 %

A Phase 2 Multi-center Pharmacodynamics Study of TVB-2640 in KRAS Mutant Non-small Cell Lung Carcinomas

Phase 2; n=18; evaluation: not stated. Reported fields: Disease Control Rate of TVB-2640 = 16 Participants ; -; -

MC1633 Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy

Phase 2; n=17; evaluation: not stated. Reported fields: ORR = 0.333 proportion of patients (90% Confidence Interval, 0.142 - 0.577); -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Denifanstat addresses Acne Vulgaris, Recurrent Glioblastoma, Metabolic Dysfunction Associated Steatohepatitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-01-18	Ascletis will collaborate with 3V Biosciences to develop and market ASC-40, ASC-60, and related compounds for the treatment of NASH and solid tumors in Greater China.	Not disclosed	US$122.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combinations of FASN inhibitors and GLP-1 agonists for liver diseases”. The milestone feed surfaced a patent-application signal described as “Combination therapies of FASN inhibitors with thyroid hormone receptor agonists”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO